Man Group PLC Novo Cure LTD Transaction History

Man Group PLC

$37.2 Billion
Q1 2025

A detailed history of Man Group PLC transactions in Novo Cure LTD stock. As of the latest transaction made, Man Group PLC holds 15,181 shares of NVCR stock, worth $249,727. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,181

Holding current value

$249,727

% of portfolio

0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$17.82 - $30.19 $270,525 - $458,314	15,181 New	15,181 $270,000
Q2 2024 Aug 14, 2024	SELL	$11.83 - $24.05 $2.88 Million - $5.86 Million	-243,653 Reduced 44.8%	300,171 $5.14 Million
Q1 2024 May 15, 2024	BUY	$12.42 - $17.29 $4.8 Million - $6.68 Million	386,436 Added 245.53%	543,824 $8.5 Million
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $120,437 - $170,755	10,821 Added 7.38%	157,388 $2.35 Million
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $754,366 - $1.98 Million	46,710 Added 46.78%	146,567 $2.37 Million
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $1.23 Million - $2.51 Million	30,466 Added 43.9%	99,857 $4.14 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $3.92 Million - $8.24 Million	69,391 New	69,391 $4.17 Million
Q3 2022 Nov 14, 2022	BUY	$67.99 - $89.57 $203,290 - $267,814	2,990 New	2,990 $227,000
Q2 2022 Aug 15, 2022	SELL	$56.6 - $89.9 $2.02 Million - $3.21 Million	-35,722 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $2.97 Million - $4.18 Million	-49,448 Reduced 58.06%	35,722 $2.96 Million
Q4 2021 Feb 14, 2022	SELL	$75.08 - $121.99 $218,933 - $355,722	-2,916 Reduced 3.31%	85,170 $6.4 Million
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $5.31 Million - $8.9 Million	45,727 Added 107.95%	88,086 $10.2 Million
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $140,440 - $242,949	1,077 Added 2.61%	42,359 $9.4 Million
Q1 2021 May 17, 2021	BUY	$124.11 - $190.17 $530,570 - $812,976	4,275 Added 11.55%	41,282 $5.46 Million
Q4 2020 Feb 16, 2021	SELL	$112.16 - $174.14 $3.62 Million - $5.62 Million	-32,282 Reduced 46.59%	37,007 $6.4 Million
Q3 2020 Nov 16, 2020	BUY	$58.05 - $111.31 $604,590 - $1.16 Million	10,415 Added 17.69%	69,289 $7.71 Million
Q2 2020 Aug 14, 2020	BUY	$57.2 - $74.41 $1.91 Million - $2.49 Million	33,437 Added 131.45%	58,874 $3.49 Million
Q1 2020 May 15, 2020	SELL	$57.05 - $95.75 $624,640 - $1.05 Million	-10,949 Reduced 30.09%	25,437 $1.71 Million
Q4 2019 Feb 18, 2020	BUY	$68.3 - $93.8 $1.78 Million - $2.45 Million	26,086 Added 253.26%	36,386 $3.07 Million
Q3 2019 Nov 14, 2019	SELL	$61.86 - $97.8 $2.12 Million - $3.35 Million	-34,226 Reduced 76.87%	10,300 $770,000
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $1.54 Million - $2.31 Million	36,533 Added 457.06%	44,526 $2.82 Million
Q1 2019 May 15, 2019	SELL	$31.96 - $56.12 $191,472 - $336,214	-5,991 Reduced 42.84%	7,993 $385,000
Q4 2018 Feb 14, 2019	SELL	$28.72 - $52.63 $4.5 Million - $8.25 Million	-156,772 Reduced 91.81%	13,984 $468,000
Q3 2018 Nov 14, 2018	BUY	$32.0 - $52.4 $724,192 - $1.19 Million	22,631 Added 15.28%	170,756 $8.95 Million
Q2 2018 Aug 14, 2018	BUY	$19.85 - $32.0 $123,228 - $198,656	6,208 Added 4.37%	148,125 $4.64 Million
Q1 2018 May 15, 2018	BUY	$19.3 - $23.65 $2.74 Million - $3.36 Million	141,917 New	141,917 $3.09 Million

Others Institutions Holding NVCR

# of Institutions

266

Shares Held

79.4M

Call Options Held

970K

Put Options Held

118K

Black Rock Inc. New York, NY

12.1M
Shares

$200 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

11.3M
Shares

$185 Million
0.0% of portfolio
Capital International Investors Los Angeles, CA

8.95M
Shares

$147 Million
0.03% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

5.52M
Shares

$90.8 Million
8.14% of portfolio
Capital World Investors Los Angeles, CA

5.22M
Shares

$85.8 Million
0.02% of portfolio

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.73B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account